CIBULA, D., ROB, L., MALLMANN, P., KNAPP, P., KLAT, J., CHOVANEC, J., MINÁŘ, L., MELICHAR, B., HEIN, A., KIESZKO, D., PLUTA, M., ŠPAČEK, J., BARTOŠ, P., WIMBERGER, P., MADRY, R., MARKOWSKA, J., STREB, J., VALHA, P., BIN HASSAN, H. I., PECEN, L., GALLUZZI, L., FUČÍKOVÁ, J., HRNČIAROVÁ, T., HRAŠKA, M., BARTŮŇKOVÁ, J., SPÍŠEK, R. Dendritic Cell-based Immunotherapy (DCVAC/OvCa) Combined with Second-line Chemotherapy in Platinum-sensitive Ovarian Cancer (SOV02): A Randomized, Open-label, Phase 2 Trial. Gynecologic Oncology. 2021, 162(3), 652-660. ISSN 0090-8258. E-ISSN 1095-6859. Dostupné z: https://doi.org/10.1016/j.ygyno.2021.07.003.